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Summary	1	
Introduction.	 Adrenocortical	 carcinoma	 (ACC)	 is	 a	 rare	 tumor	 characterized	 by	 poor	2	
prognosis	in	most	cases.	Moreover,	in	most	cases	ACC	produces	an	excess	of	adrenal	steroid	3	 hormones	with	relevant	clinical	consequences.		4	
Areas	 covered.	 After	 an	 extensive	 literature	 search,	 this	 narrative	 review	 addresses	5	 diagnostic	management,	 including	 hormonal,	 radiological	 and	 pathological	 assessment,	 and	6	 treatment,	 which	 should	 be	 directed	 toward	 both	 cancer	 and	 hormone	 related	 problems.		7	 While	surgery	is	the	first	option	in	ACC	without	evidence	of	metastatic	disease,	and	the	only	8	 possibility	of	cure,	the	therapeutic	management	of	metastatic	patients	is	centered	on	systemic	9	 therapy	including	mitotane	alone	or	in	combination	with	chemotherapy.	Mitotane	is	also	used	10	 in	 adjuvant	 setting,	 because	 up	 to	 80%	 of	 patients	 with	 non-metastatic	 ACC	 show	 loco-11	 regional	or	distant	metastases	after	an	apparent	complete	surgical	excision.	12	
Expert	 Commentary:	 Management	 of	 ACC	 patients	 is	 fraught	 with	 many	 difficulties	 and	13	 should	 be	 limited	 to	 experienced	 physicians.	 Each	 step	 of	 clinical	 management,	 such	 as	14	 diagnosis,	prognostication,	 treatment	 (both	 surgical	 and	medical)	 is	 challenging	and	 carries	15	 the	 possibility	 of	 severe	mistakes.	 For	 this	 reasons,	 each	 step	 of	 the	management	 strategy	16	 should	 be	 decided	 in	 the	 setting	 of	 a	 multi-disciplinary	 team	 including	 different	 expertise	17	 (endocrinology,	radiology,	pathology,	oncology),	in	expert	centers.	18	
	19	
1.	DIAGNOSIS	20	 Adrenocortical	 carcinoma	 (ACC)	 is	 a	 rare	 tumor	 (0.5-2	 cases	 per	million	 per	 year)	with	 a	21	
peak	 incidence	between	40-60	years,	and	with	women	being	more	affected	(55-60%)	22	
[1,	2].	ACC	is	characterized	by	a	poor	prognosis	in	most	cases	[3].	However,	prognosis	is	23	
heterogeneous	being	mainly	influenced	by	tumor	stage	at	diagnosis	(5-year	survival	rate	is	24	 81,	 61,	 50,	 and	 13	%,	 respectively,	 from	 stage	 1	 to	 stage	 4)	 and	 completeness	 of	 surgical	25	
	 4	
extirpation	[4].	ACC	usually	present	as	a	sporadic	tumor,	but	can	be	encountered	in	the	1	
setting	 of	 hereditary	 tumor	 syndromes,	 such	 as	 Li	 Fraumeni	 (TP53	 germline	 and	2	
somatic	mutations),	familial	adenomatous	polyposis	coli	(β-catenin	somatic	mutations)	3	
and	Beckwith–Wiedeman	(IGF-2	overexpression)	[5]	4	
The	 diagnostic	 approach	 to	 any	 adrenal	 mass	 should	 include	 use	 of	 high-resolution	5	
imaging	 techniques	 to	ascertain	 the	 risk	of	malignancy.	 In	 current	practice,	CT	 is	 the	6	
most	frequently	used	test	for	this	aim	and	also	for	staging	purpose.	MRI	and	FDG-PET	7	
are	often	used	as	second-line	tests,	when	CT	findings	are	inconclusive	[3,	6-8].	There	is	8	
still	 insufficient	 evidence	 to	 judge	 which	 modality	 is	 superior	 [9];	 however,	9	
unenhanced	CT	is	generally	considered	the	primary	imaging	test	to	exclude	an	adrenal	10	
malignancy,	in	presence	of	a	homogeneous	adrenal	mass	with	density	≤	10	Hounsfield	11	
Units	and	size	≤	4	cm	[7].	When	an	adrenal	mass	is	suspected	to	be	an	ACC,	it	is	key	to	12	
conduct	a	 full	staging	by	extending	 imaging	evaluation	to	the	thorax	and	pelvis,	since	13	
ACC	may	present	with	distant	metastases	in	about	25%	of	cases	[3,	4,	6,	7,	8].	14	 ACC	has	the	propensity	to	produce	and	secrete	steroids;	 thus,	 in	all	patients	with	suspected	15	 ACC,	 signs	 and	 symptoms	 of	 cortisol,	 aldosterone,	 and	 sex	 steroids	 should	 be	 actively	16	 investigated	 [6].	Concomitant	 secretion	of	different	 steroids	 is	 a	hallmark	of	ACC.	The	most	17	 frequent	condition	is	a	cortisol-secreting	ACC	causing	a	Cushingoid	phenotype	including	facial	18	 plethora,	 easy	 bruising,	 weight	 gain,	 proximal	 myopathy,	 severe	 hypertension	 and	19	 uncontrolled	 diabetes	 mellitus.	 Hypokalemia	 is	 common	 with	 severe	 hypercortisolism	20	 because	 mineralocorticoid	 receptors	 are	 triggered	 by	 the	 large	 amount	 of	 cortisol	 that	21	 overwhelms	 the	 inactivating	 capacity	 of	 corticosteroid	 11β-dehydrogenase	 isoenzyme	 2	22	 (HSD11B2).	 Women	 frequently	 complain	 of	 acne,	 hirsutism,	 and	 oligomenorrhea	 [3].	 The	23	 differential	 diagnosis	 in	 these	 situations	 is	 PCOS,	 especially	 with	 mild	 or	 subclinical	24	 hypercortisolism.	Clinical	clues	 that	are	helpful	 to	 the	diagnosis	of	ACC	are	 the	concomitant	25	
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existence	 of	 a	 Cushingoid	 phenotype	 with	 signs	 of	 marked	 androgen	 excess,	 with	 cancer-1	 related	 symptoms	 (anorexia,	 cachexia,	 mass	 effect).	 With	 rapidly	 growing	 tumors,	 cancer-2	 related	 features	 dominate	 the	 clinical	 presentation.	 ACC	 can	 also	 cause	 deep	 venous	3	 thrombosis	or	pulmonary	embolism	due	to	either	cortisol	excess	or	malignancy	[3].	Moreover,	4	 the	presence	of	cortisol	excess	may	consistently	increase	the	toxicity	of	chemotherapy	since	it	5	 is	 associated	 with	 immune	 depression	 that	 may	 favor	 infections	 particularly	 in	 the	6	 neutropenia	 phase.	 Cortisol	 excess	 should	 be	 excluded	 in	 all	 patients	 with	 suspected	 ACC,	7	 even	if	they	do	not	present	with	typical	Cushing	features	[7].	8	 A	detailed	hormonal	work-up	 (Table	 1)	 should	be	performed	preoperatively	 in	all	patients	9	 with	suspected	ACC	for	the	following	reasons:		10	 i) Demonstration	 of	 steroid	 excess	 establishes	 the	 adrenocortical	 origin	 of	 the	11	 tumor,	 while	 other	 differential	 diagnoses	 are	 being	 ruled	 out	 (i.e.	 lymphoma,	12	 sarcoma);	13	 ii) The	 steroid	 profile	 may	 be	 helpful	 to	 evaluate	 the	 malignant	 potential	 (i.e.	14	 estradiol	 excess	 in	 males,	 high	 concentration	 of	 dehydroepiandrosterone	15	 sulphate	–DHEAS-	or	steroid	precursors);		16	 iii) Presence	of	autonomous	cortisol	secretion	in	a	patient	with	ACC	indicates	a	risk	17	 of	 post-operative	 adrenal	 insufficiency,	 which	 can	 be	 potentially	 life-18	 threatening;		19	 iv) Demonstration	of	steroid	excess	at	baseline	establishes	tumor	markers	that	can	20	 be	useful	to	detect	persistence	or	recurrence	of	disease	postoperatively	[3,	8].		21	 A	 standard	 1	 mg	 overnight	 dexamethasone	 test	 (1-mg	 DST)	 is	 recommended	 to	 exclude	22	
autonomous	 cortisol	 secretion	 in	 accordance	 with	 low	 or	 suppress	 levels	 of	 ACTH,	23	 similar	 with	 adrenal	 incidentaloma	 [7]	 This	 test	 has	 higher	 sensitivity	 (95%	 at	 a	 cortisol	24	 threshold	of	1.8	μg/dL),	compared	with	24-h	urinary-free	cortisol	(UFC)	which	is	not	helpful	25	
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in	 cases	 of	 mild	 hypercortisolism	 [10].	 If	 cortisol	 levels	 following	 the	 1-mg	 DST	 are	 not	1	 suppressed	despite	 lack	of	overt	 Cushing	 syndrome,	 the	condition	of	autonomous	cortisol	2	 secretion	may	be	present.	The	recent	guidelines	of	the	European	Society	of	Endocrinology	and	3	 the	European	Network	for	the	Study	of	Adrenal	Tumors	(ENSAT)	promoted	this	definition	to	4	 the	classic	“subclinical	Cushing’s	syndrome”	[7].	Autonomous	cortisol	secretion	is	certain	for	a	5	 cortisol	 levels	above	5	μg/dL	after	1-mg	DST,	while	values	between	1.8	μg/dL	and	5	μg/dL	6	 require	 additional	 investigation	 to	 confirm	 the	 diagnosis	 [7].	 Recognizing	 asymptomatic	7	 cortisol	 excess	 preoperatively	 identifies	 the	 patients	 who	 benefit	 from	 glucocorticoid	8	 replacement	in	anesthesia	induction	and	after	adrenalectomy	and	during	follow-up	[11].		9	 Aldosterone-producing	ACC	is	rare	and	is	generally	associated	with	severe	hypertension	and	10	 marked	 hypokalemia	 [12].	 Screening	 by	 measuring	 plasma	 aldosterone	 and	 plasma	 renin	11	 activity	 (PRA)	 (or	 direct	 renin	 concentration)	 is	 recommended	 in	 all	 hypertensive	 and/or	12	 hypokalemic	 patients	 with	 adrenal	 masses	 [13].	 In	 some	 cases,	 pseudo-aldosteronism	 is	13	 present,	due	to	increased	production	of	deoxycorticosterone.	Pure	estrogen	excess	is	rare	and	14	 may	 cause	 gynecomastia,	 loss	 of	 libido	 and	 testicular	 atrophy	 in	 men,	 while	 in	 women	15	
menstrual	 irregularities	 [8].	Hypersecretion	 of	 sexual	 steroids	 is	 frequently	 associated	 to	16	 cortisol	excess	in	ACC	patients.	Baseline	17-OH	progesterone	levels	are	frequently	increased,	17	 as	well	as	androstenedione	and	DHEAS,	which	 leads	 to	 increased	plasma	testosterone	 in	18	
females	with	 signs	 of	 androgen	 excess	 (hirsutism,	 acne,	 alopecia)	 [3].	Measurement	of	19	 steroid	precursors	in	blood	or	urine	may	be	exploited	for	diagnostic	purposes.	However,	the	20	 value	of	increased	DHEAS	levels	to	predict	malignancy	of	an	adrenal	mass	is	rather	low	[14].	21	 More	recently,	it	was	demonstrated	that	serum	steroid	paneling	by	LC-MS/MS	is	a	useful	tool	22	 to	 discriminate	 ACC	 from	 other	 adrenal	 tumor	 lesions.	 In	 this	 study,	 both	 the	 number	 of	23	 steroids	secreted	in	high	amounts	and	the	marked	elevation	of	several	steroid	intermediates	24	 without	biological	activity	was	characteristic	of	ACC	and	useful	for	the	differential	diagnosis.	25	
	 7	
The	cortisol	precursor	11-deoxycortisol	was	found	the	most	discriminating	between	ACC	and	1	 non-ACC	adrenal	lesions	[15].	2	 Assessment	 of	 plasma	 or	 urine	 fractionated	metanephrines	 is	 recommend	 in	 patients	with	3	 suspected	 ACC	 to	 exclude	 a	 pheochromocytoma,	 and	 avoid	 misdiagnosis	 and	 unexpected	4	 intraoperative	 complications	 [3,	 7,	 16].	 Pertinently,	 the	 radiological	 imaging	 of	5	 pheochromocytoma	 may	 appear	 as	 a	 large,	 heterogeneous	 and	 hypervascularized	 mass	6	 mimicking	ACC	and	rarely	pheocromocytoma	may	present	with	hypercortisolism,	being	7	
due	to	ectopic	ACTH	production	[17].	8	 Finally,	 the	 hormonal	 assessment	 is	 fundamental	 because	 treatment	 should	 be	 directed	9	 toward	both	cancer	and	hormones,	and	the	therapeutic	approach	varies	according	to	the	stage	10	 at	diagnosis	and	clinical	conditions	of	patients.	However,	it	is	important	to	recognize	non-11	
specific	 symptoms	 due	 to	 the	 mass	 effect,	 including	 abdominal	 discomfort	 (nausea,	12	
vomiting,	 abdominal	 fullness)	 and	 back	 pain,	 while	 classical	 malignancy-associated	13	
symptoms	 such	 as	 weight	 loss,	 night	 sweats,	 fatigue	 or	 fever	 are	 less	 frequently	14	
observed	[8].		15	
All	patients	with	 suspected	or	proven	ACC	should	be	discussed	 in	a	multidisciplinary	16	
expert	 team	meeting	 (including	 the	 following	 specialists:	 endocrinologist,	 oncologist,	17	
surgeon,	radiologist,	pathologist)	at	least	at	the	time	of	initial	diagnosis	and	at	critical	18	
points	during	the	disease	course	(e.g.	tumor	recurrence,	progression).	The	team	should	19	
have	access	to	adrenal-specific	expertise	in	interventional	radiology,	radiation	therapy,	20	
nuclear	medicine,	and	genetics	as	well	as	to	palliative	care	facilities.	21	
	22	
2.	PROGNOSTIC	FACTORS		23	
ACC	stage	and	a	margin-free	resection	are	important	and	validated	prognostic	factors	24	
[3,	4,	6].		Currently,	the	ENSAT	staging	system	is	the	most	frequently	used	and	allows	a	25	
	 8	
clear	 stratification	 of	 prognosis	 by	 stage	 [4].	 Resection	 status	 Rx	 (unknown),	 R1	1	
(microscopically	 positive	 margins)	 and	 R2	 (macroscopically	 positive	 margins)	 are	2	
associated	with	progressively	reduced	survival	irrespectively	of	other	risk	factors	[3,	4,	3	
6].	The	proliferation	activity	of	the	tumor	influences	the	risk	of	recurrence	following	R0	4	
surgery	 and	 proliferation	 is	 currently	 assessed	 by	 the	 immunohistochemical	5	
evaluation	 of	 the	 Ki-67	 index,	 despite	 some	 problems	 to	 harmonize	 readings	 among	6	
different	pathologists.	Higher	values	of	Ki-67	index	are	consistently	associated	with	a	7	
worse	 prognosis	 and,	 in	 a	 multicenter	 study,	 a	 Ki-67	 value	 at	 10%	 was	 found	 to	8	
separate	patients	at	good	or	worse	prognosis,	in	terms	of	risk	of	recurrence	following	9	
complete	resection	[18].	Assessment	of	the	mitotic	index	carries	the	same	information,	10	
and	a	cutoff	at	>20	mitoses	per	50	high-power	field	has	been	established	to	define	high-11	
grade	 tumors	 [19].	 However,	 studies	 correlating	 the	 two	 proliferation	 indexes	 are	12	
lacking.		13	
The	role	of	overt	cortisol	excess	as	a	negative	prognostic	factor	has	been	consistently	14	
confirmed	 in	 a	 number	 of	 studies	 showing	 an	 association	 between	 cortisol	15	
overproduction	and	shorter	survival.	Interestingly,	cortisol	excess	was	an	independent	16	
prognostic	factor	either	in	patients	with	advanced	ACC	[20,	21]	or	following	complete	17	
tumor	 resection	 [22].	 Therefore,	 cortisol	 excess	 confers	 a	 negative	 prognostic	 effect	18	
beyond	 its	 expected	 detrimental	 impact	 on	 patient’s	 conditions	 and	 it	 is	 likely	 a	19	
hallmark	of	increased	biological	aggressivity.	20	
	21	
3.	SURGICAL	TREATMENT	22	 Surgery	is	the	first	option	in	ACC	without	evidence	of	metastatic	disease	(stages	I–III)	and	the	23	 only	possibility	of	cure.	The	5-year	survival	rate	is	approximately	55%	when	radical	resection	24	 is	 possible	 [23].	 In	 patients	 with	 infiltrating	 tumor	 or	 suspected	 lymph	 nodes	 open	25	
	 9	
adrenalectomy	 (OA)	 is	 recommended;	 on	 the	 contrary,	 a	 localized	 ACC	 (I-II	 stage)	 can	 be	1	 removed	by	laparoscopic	adrenalectomy	(LA)	or	by	OA	[6],	although	the	use	of	laparoscopic	2	 approach	in	this	setting	is	still	debated.	Literature	is	indeed	discordant:	Huynh	and	colleagues	3	 [24]	showed	that	use	of	LA	may	decrease	survival	in	patients	with	stage	II	ACC,	while	most	4	
of	 the	 other	 studies	 failed	 to	demonstrated	significant	different	outcomes	between	LA	and	5	 OA	 [25-28].	 In	 these	 studies,	 the	 recurrence	 rate	 was	 54%,	 50%,	 53%,	 and	 49%,	6	
respectively,	 after	 LA	 compared	 to	61%,	64%,	65%,	 and	64%,	 respectively,	 after	OA.	7	
However,	 a	 study	 raised	 concern	 about	 the	 most	 frequent	 occurrence	 of	 peritoneal	8	
carcinomatosis	with	 the	 use	 of	 LA	 [29].	However,	all	 these	studies	are	retrospective	and	9	 likely	 prone	 to	 selection	 bias,	 and	 no	 prospective	 trials	 are	 available	 at	 this	 moment.	10	 Whatever	the	surgical	approach,	surgery	must	be	performed	by	an	extremely	skilled	surgical	11	 team,	 in	 centers	with	 high	 volume	 of	 adrenalectomies	 per	 year	 [30],	with	 the	 goal	 of	 a	 R0	12	 resection	(microscopically	free	margins).		13	 Despite	 state-of-the-art	 surgery	 recurrence	 after	 intervention	 is	 frequent.	 Since	 an	 early	14	 detection	 of	 local	 recurrence	 or	 limited	 metastatic	 disease	 can	 open	 the	 possibility	 of	 a	15	 complete	resection	associated	with	a	long	RFS	[31],	a	tight	follow-up	is	mandatory.	Hormonal	16	 assessment	and	imaging	(total-body	CT)	should	be	done	every	3	months	for	at	 least	2	years	17	 after	 surgery.	 After	 this	 period,	 intervals	 could	 be	 gradually	 increased,	 but	 also	 in	 patients	18	 without	evidence	of	disease	follow-up	is	recommended	in	the	long	period	[6].	19	
	20	
4.	SYSTEMIC	TREATMENT	21	
	22	
4.1	ADJUVANT	TREATMENT	23	 Despite	 an	 apparent	 complete	 surgical	 excision,	 up	 to	 80%	 of	 patients	 show	 loco-regional	24	 recurrence	 or	 distant	 metastases.	 To	 reduce	 the	 high	 rate	 of	 recurrence,	 most	 centers	25	
	 10	
recommend	adjuvant	treatment	with	mitotane	(o,p’-DDD),	available	in	500-mg	tablets	for	oral	1	 administration.	 Mitotane	 is	 an	 adrenolytic	 drug,	 a	 parent	 compound	 of	 the	 insecticide	2	 dichlorodiphenyltrichloroethane	-	DDT,	able	to	inhibit	gene	expression	of	various	cytochrome	3	 P450-dependent	 mitochondrial	 enzymes	 of	 the	 steroidogenetic	 pathway	 [20,22	 desmolase	4	 (CYP11A1),	11β-hydroxylase	(CYP11B1)	and	18β-hydrolase	(CYP11B2)]	[32].		5	 Use	 of	 adjuvant	mitotane	 in	ACC	was	 first	 proposed	by	 Schteingart	 and	 colleagues	 in	 1982	6	 [33].		No	data	from	randomized	trials	are	available;	however,	convincing	results	in	support	of	7	 adjuvant	 therapy	 with	 mitotane	 were	 provided	 by	 a	 large	 retrospective	 study	 of	 ours,	8	 including	 177	 patients	 from	 different	 Italian	 and	 German	 centers.	 A	 group	 of	 patients	9	 underwent	adjuvant	therapy	with	mitotane	after	surgery	while	patients	of	two	contemporary	10	 independent	 control	 groups	 were	 followed	 without	 any	 therapy.	 Recurrence-free	 survival	11	 (RFS)	was	significantly	 longer	 (p	<0.0001)	 in	 the	47	patients	 treated	with	adjuvant	 therapy	12	 (42	months)	compared	to	the	groups	of	55	and	75	patients	not	treated	after	surgery	(10	and	13	 25	 months,	 respectively).	 Also	 overall	 survival	 (OS)	 was	 significantly	 prolonged	 in	 the	14	 mitotane	 group	 (110	 months)	 compared	 to	 the	 two	 control	 groups	 (52	 and	 67	 months,	15	 respectively)	[34].	Recently,	our	group	has	updated	the	follow-up	of	these	cohorts	of	patients	16	 with	almost	10	years	of	additional	observation,	confirming	that	adjuvant	mitotane	treatment	17	 is	associated	with	a	significant	benefit	 in	 terms	of	RFS	regardless	of	 the	hormone	secretory	18	 status	 [35].	 Advantage	 in	 OS	 was	 less	 evident	 but	 this	 may	 be	 explained	 by	 the	 fact	 that	19	 mitotane	 was	 introduced	 as	 treatment	 of	 ACC	 recurrence	 in	 most	 patients.	 Despite	 its	20	 retrospective	nature,	this	study	remains	the	most	informative	piece	of	evidence	on	the	topic	21	 and	represents	a	reference	for	decision	making	in	ACC	patients.	Strengths	of	the	study	are	the	22	 inclusion	of	 contemporary	groups	of	matched	patients,	who	were	allocated	 to	 treatment	or	23	 follow-up	based	on	the	treatment	policy	the	center.		24	
	 11	
Conversely,	 in	 many	 studies	 patients	 with	 unfavorable	 characteristics	 were	 more	 likely	1	 selected	for	adjuvant	mitotane,	thus	introducing	a	bias.	An	example	of	this	may	be	found	in	a	2	 recent	 study	 reporting	 a	multicenter,	 retrospective	 analysis	 on	 207	 ACC	 patients,	 showing	3	 that	 adjuvant	 mitotane	 was	 associated	 with	 decreased	 RFS.	 However,	 42%	 of	 the	 patients	4	 treated	with	mitotane	had	stage	IV	ACC	and,	indeed,	chemotherapy	was	frequently	associated	5	 to	mitotane	therapy	[36].	A	retrospective	study	from	the	University	of	Michigan	confirmed	the	6	 finding	 that	 adjuvant	 mitotane	 treatment	 is	 associated	 with	 a	 significantly	 improved	 RFS	7	 although	it	 failed	to	prolong	significantly	OS	[37].	The	lack	of	effect	on	OS	may	be	explained	8	 with	the	short	follow-up	(25.6	months).	9	 Despite	controversy	on	this	issue,	there	is	general	agreement	on	the	adjuvant	use	of	mitotane	10	 following	 surgical	 removal	 of	 ACC	 in	 high-risk	 patients.	 The	 condition	 of	 high	 risk	 of	11	 recurrence	 has	 been	 defined	 as	 stage	 III,	 or	 Ki-67	 >10%,	 or	 Rx-R1	 resection	 by	 a	 panel	 of	12	 international	 experts	 [38].	 For	 low	 risk	patients,	who	 are	 characterized	by	 stage	 I	 or	 II,	 R0	13	 resection	 and	 Ki-67	 ≤10%,	 adjuvant	 mitotane	 therapy	 is	 not	 mandatory.	 An	 international,	14	 multicentric,	prospective,	randomized	trial	(ADIUVO	trial)	is	currently	enrolling	low-risk	ACC	15	 patients,	who	are	randomized	to	mitotane	or	observation,	in	order	to	definitely	establish	the	16	 effectiveness	of	adjuvant	mitotane	in	this	set	of	patients.		17	 It	 is	common	practice	 in	expert	centers	 to	monitor	regularly	blood	mitotane	concentrations	18	 during	 treatment	 and	 to	 target	 levels	 of	 14–20	 mg/L	 [39].	 A	 retrospective	 analysis	19	 demonstrated	 that	 blood	 mitotane	 concentrations	 ≥14	 mg/L	 were	 associated	 with	 a	20	 prolonged	RFS	 in	patients	 treated	with	adjuvant	mitotane	 following	macroscopically	radical	21	 surgery	[40].	Thus,	maintenance	of	target	mitotane	concentration	may	represent	a	predictor	22	 of	response	to	adjuvant	treatment.		23	 There	is	no	consensus	on	how	to	start	treatment:	the	ESMO	guidelines	[38]	recommend	that	24	 mitotane	 therapy	 should	 be	 administered	 following	 a	 high-dose	 regimen	 with	 the	 aim	 of	25	
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reaching	 a	 daily	 dose	 of	 6	 g/daily	 rather	 soon	 and	 then	 adjust	 the	 dose	 according	 to	1	 tolerability	and	mitotane	 levels.	 In	our	personal	practice,	we	start	 treatment	at	 lower	doses	2	 (Table	2)	because	they	are	better	tolerated	and	less	patients	have	to	discontinue	treatment	3	 [29].	Adjuvant	mitotane	treatment	is	started	as	soon	as	possible	and	usually	no	longer	4	
than	12	weeks	 following	 surgery,	 even	 if	 there	 are	no	data	 showing	what	 is	 the	best	5	
timing.	Duration	of	adjuvant	mitotane	therapy	has	not	been	definitively	established,	but	it	is	6	 reasonable	to	continue	therapy	for	at	 least	2	years,	because	this	 is	 the	period	when	most	of	7	 ACC	recurrences	are	detected.	In	our	practice,	we	have	currently	extended	treatment	till	to	3	8	 to	5	years,	if	tolerated.				9	 The	most	common	unwanted	effects	are	gastrointestinal	manifestations	that	appear	early	in	10	 the	 course	 of	 treatment,	 independently	 on	 mitotane	 levels	 [41].	 Diarrhea	 and	 nausea	 are	11	 particularly	 frequent	 and	 can	 be	 managed	 with	 temporary	 dose	 reduction	 and	 supportive	12	 therapy.	 Elevated	 g-glutamyl-transferase	 levels	 are	 also	 frequently	 observed	 but	 are	 not	13	 actually	 troublesome	 unless	 values	 are	 exceedingly	 elevated.	 Clinically	 significant	 liver	14	 toxicity	 is	 characterized	 by	 a	 marked	 increase	 in	 transaminases	 and	 bilirubin,	 but	 is	15	 infrequently	 observed	 in	 the	 absence	 of	 predisposing	 conditions	 [39].	 Central	 neurologic	16	 toxicity	 (cerebellar	 symptoms,	 disturbed	 cognitive	 performance)	 is	more	 closely	 associated	17	 with	 elevated	 mitotane	 concentrations	 (20	 mg/L)	 but	 subtler	 symptoms,	 such	 as	 memory	18	 impairment	 or	 attention	 deficit,	 may	 be	 observed	 in	 some	 patients	 even	 at	 lower	 drug	19	 concentrations	[42].	In	this	context,	monitoring	of	circulating	mitotane	levels	may	be	useful	to	20	 tailor	 individually	 the	 therapy	 and	 limit	 side	 effects	 thus	 attaining	 better	 compliance	 to	21	 treatment.	The	implementation	of	blood	mitotane	monitoring,	through	a	service	provided	in	22	 Europe	by	 the	 company	distributing	Lysodren®	(Lysosafe,	www.lysodren-europe.com),	has	23	 rendered	the	use	of	this	drug	more	feasible	because	it	is	possible	to	some	extent	to	anticipate	24	 and	 prevent	 toxicity.	 In	 our	 current	 practice,	 measurement	 of	 circulating	 mitotane	25	
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concentration	has	become	mandatory	for	a	proper	management	of	patients	with	ACC.	At	our	1	
center,	 monitoring	 of	 mitotane	 concentrations	 is	 done	 every	 month	 in	 the	 starting	2	
phase	 of	 treatment,	 and	 then	 every	 3	 months	 once	 mitotane	 levels	 are	 at	 plateau;	3	
moreover,	 additional	monitoring	 is	 adjusted	 according	 to	 clinical	 needs.	Biochemical	4	
monitoring	 includes	 also	 blood	 count,	 liver	 function	 tests,	 creatinine,	 electrolytes,	5	
glucose,	 lipids,	 ACTH,	 cortisol,	 PRA,	 testosterone,	 DHEAS,	 17-hydroxyprogesterone,	6	
androstenedione,	LH,	FSH,	TSH,	FT4.		7	 A	general	measure	 to	deal	with	mitotane	toxicity	 is	a	step	down	to	 the	previously	 tolerated	8	 dose,	 or	 temporary	 drug	 withdrawal	 in	 the	 event	 of	 severe	 manifestations	 (Table	 2).	9	 However,	 well-informed	 and	 motivated	 patients	 are	 able	 to	 cope	 with	 side	 effects	 and	10	 maintain	compliance	to	treatment.	To	accomplish	this	task,	it	is	important	to	establish	a	close	11	 patient–physician	relationship	to	induce	and	maintain	adherence	to	treatment.	Patients	seek	12	 advice	frequently,	also	because	their	local	physicians	are	unfamiliar	with	mitotane	use	and	its	13	 attendant	 complications,	 and	 it	 is	necessary	 to	give	a	 timely	 counseling	 to	keep	patients	on	14	 treatment.		15	 Mitotane	 has	 a	 wide	 range	 of	 effects	 on	 the	 endocrine	 system	 and	 may	 potentially	 cause	16	 several	endocrine	disturbances	 that	 should	be	carefully	managed	 (Table	 3).	Because	of	 the	17	 adrenolytic	 effect	 of	 mitotane,	 all	 patients	 should	 receive	 glucocorticoid	 replacement	 to	18	 prevent	adrenal	insufficiency.	Steroid	doses	are	typically	higher	than	in	Addison’s	disease,	due	19	 to	an	enhanced	metabolic	clearance	rate	of	glucocorticoids	induced	by	mitotane	[3,	6,	43].	An	20	 inadequate	treatment	of	adrenal	insufficiency	increases	mitotane-related	toxicity,	particularly	21	 gastrointestinal	side	effects,	and	reduces	tolerance	[30].	Mineralocorticoid	supplementation	is	22	 not	mandatory	in	all	patients	because	the	zona	glomerulosa	is	partly	spared	by	the	toxic	effect	23	 of	 mitotane	 [44].	 Moreover,	 mitotane	 affects	 thyroid	 and	 gonadal	 function	 by	mechanisms	24	 that	are	still	to	be	completely	elucidated.	Mitotane	administration	is	associated	with	low	FT4	25	
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levels	 without	 a	 compensatory	 rise	 in	 TSH,	 an	 effect	 that	 becomes	 apparent	 early	 in	 the	1	 course	of	 treatment.	This	prompts	thyroxin	replacement,	even	if	 the	benefit	of	 this	measure	2	 may	be	difficult	to	appreciate	[42,	44].	In	women,	gonadal	function	is	usually	preserved	and	3	 most	female	patients	have	regular	cycles	unless	PRL	levels	are	significantly	increased	[6,	42,	4	 44]	 due	 to	 a	 weak	 estrogen-like	 action	 of	 mitotane	 [45].	 Conversely,	 in	 men	 mitotane	5	 treatment	causes	sexual	dysfunction	as	a	late	but	common	unwanted	effect,	due	to	inhibition	6	 of	 testosterone	 secretion.	 Sex	 steroid	 replacement	 may	 become	 necessary	 to	 treat	7	 hypogonadism	 in	 some	 patients	 but	may	worsen	 gynecomastia	 [6,	 42,	 44].	Mitotane	 use	 is	8	 associated	with	increasing	levels	of	LDL	and	HDL	cholesterol,	and	triglycerides	[46].	However,	9	 the	value	of	 introducing	 statins	 remains	uncertain	 although	patients	may	be	worried	about	10	 their	 lipid	 levels.	 The	 decision	 to	 use	 anti-lipid	 drugs,	 which	 may	 further	 complicate	11	 supportive	 therapy	and	 is	not	exempt	 from	potential	 toxicity,	 should	be	 carefully	 though	at	12	 considering	 patient	 life	 expectancy.	 Side	 effects	 of	 mitotane	 treatment	 are	 showed	 in	13	
Table	4.	14	 Another	 option	 is	 adjuvant	 radiotherapy,	 that	 in	 a	 retrospective	 analysis	 from	 the	 United	15	 States	was	reported	to	decrease	of	4.7	times	the	risk	of	 local	 failure	compared	with	surgery	16	 alone	 [47].	 In	 a	 retrospective	 analysis	 from	 the	 German	 ACC	 Registry,	 radiotherapy	 in	 an	17	 adjuvant	setting	resulted	in	a	significant	better	5-year	RFS,	but	did	not	affect	OS	and	disease-18	 free	 survival	 [48].	 However,	 no	 difference	 between	 surgery	 plus	 radiotherapy	 and	 surgery	19	 alone	was	found	in	another	retrospective	study	done	in	the	United	States	[49].	A	review	of	the	20	 literature	 concluded	 that	 adjuvant	 radiotherapy	 should	 be	 considered	 in	 patients	 with	21	 incomplete,	or	R1	resection,	or	Rx	resection,	who	are	at	high	risk	for	local	recurrence	[50].	A	22	 total	dose	of	>40	Gy	with	single	fractions	of	1.8	Gy	to	2	Gy	should	be	administered.	However,	23	 prospective	 investigations	 are	 required	 and	 no	 definitive	 conclusions	 are	 available	 at	 the	24	 moment.		25	
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As	far	as	chemotherapy	is	concerned,	limited	data	are	available.	A	recent	paper	published	data	1	 on	3982	ACC	patients	from	the	National	US	Cancer	Data	Base	(NCDB),	revealing	that	adjuvant	2	 chemotherapy	was	performed	in	10%	of	cases.	However,	the	study	was	not	able	to	capture	in	3	 how	many	cases	cytotoxic	agents	or	mitotane	have	been	used	as	adjuvant	chemotherapy.	By	4	 comparing	these	subjects	with	those	treated	with	surgery	only,	OS	was	not	different,	while	no	5	 RFS	analysis	was	reported	[51].	Anecdotal	cases	reported	a	more	favorable	outcome	after	an	6	 adjuvant	etoposide	–	cisplatin	based	chemotherapy	[52].	A	phase	II	clinical	trial	reported	that	7	 the	 combination	 of	 mitotane	 plus	 streptozotocin	 was	 effective	 in	 an	 adjuvant	 setting.	8	 However,	the	study	design	does	not	allow	discriminating	the	relative	merits	of	the	two	drugs	9	 [53].	10	
	11	
4.2	TREATMENT	OF	ADVANCED	DISEASE	12	 About	50%	of	newly	diagnosed	ACC	patients	present	with	metastatic	or	unresectable	disease	13	 [38]	and,	as	previously	said,	most	ACC	that	underwent	initial	complete	resection	are	doomed	14	 to	 develop	 recurrent	 or	 metastatic	 disease	 [38,	 39].	 The	 prognosis	 of	 patients	 with	15	 advanced/metastatic	ACC	 is	generally	poor	but	 it	 is	heterogeneous	and	 long-term	survivors	16	 have	 been	 described	 [39,	 54].	 The	 management	 of	 these	 patients	 is	 mainly	 centered	 on	17	 systemic	therapy	including	mitotane	alone	or	mitotane	in	combination	with	chemotherapy.	18	 	The	standard	chemotherapy	regimen	 for	advanced	ACC	 is	EDP	(etoposide,	doxorubicin	and	19	 cisplatin)	plus	mitotane	 (EDP-M).	This	 scheme	was	 introduced	 in	a	multicenter	prospective	20	 phase	II	study	conducted	in	Italy	[20		55].	More	recently,	its	efficacy	was	compared	against	the	21	 combination	 of	 streptozotocyn	 and	mitotane	 (Sz-M)	 in	 a	 prospective	 randomized	 phase	 III	22	 clinical	trial	conducted	worldwide	[56].	Three	hundred	and	four	patients	were	prospectively	23	 enrolled	 in	 about	 6	 years.	 Patients	 with	 disease	 progression	 to	 the	 first-line	 treatment	24	 received	 the	 alternate	 regimen.	 EDP-M	 was	 superior	 to	 Sz-M	 both	 in	 terms	 of	 disease	25	
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response	 rate	 and	 progression-free	 survival	 (PFS).	 Analysis	 of	 OS	 also	 favored	 patients	1	 initially	 randomized	 to	receive	EDP-M	but	due	 to	 the	attenuating	effect	of	 the	cross	over	 to	2	 EDP-M	 of	 patients	 who	 progressed	 to	 Sz-M,	 the	 difference	 failed	 to	 attain	 statistical	3	 significance.	In	addition	to	systemic	therapy	also	loco-regional	therapies,	i.e.	surgery	[57,	58],	4	 radiofrequency	 ablation	 (RFA)	 [58,	 59],	 and	 chemoembolization	 [60]	 can	 be	 taken	 into	5	 consideration	 in	 a	 selected	 patient	 population.	 Moreover,	 in	 patients,	 who	 have	6	 contraindications	 to	 EDP,	 or	 poor	 performance	 status,	 either	 cisplatin	 or	 carboplatin	7	 administered	as	single	agents	could	be	reasonable	options.		8	 It	 is	worth	of	note	 that	 there	 is	a	small	subgroup	of	patients	with	advanced/metastatic	ACC	9	 presenting	 an	 oligo-metastatic	 disease	with	 favorable	 prognostic	 factor	 and/or	 a	 relatively	10	 long	 disease-free	 interval	 from	 previous	 surgery	 	 (i.e.	 12	months	 or	more).	 These	 patients	11	 have	 a	 relative	 long	 survival	 perspective	 and	may	 not	 benefit	 from	 an	 aggressive	 systemic	12	 treatment	such	as	the	EDP-M	regimen.	Therefore,	single	agent	mitotane	could	be	a	reasonable	13	 option.	Mitotane	is	often	associated	with	 loco-regional	approaches	 in	the	treatment	of	these	14	 patients.	Surgery	of	primary	and	or	metastases	can	be	recommended	if	a	complete	resection	15	 (R0)	is	achievable.	Surgery	of	multiple	metastases	is	considered	on	a	case-by-case	basis	and	16	 should	be	performed	mainly	in	patients	with	favorable	prognostic	factors,	sustained	disease	17	 response	to	systemic	 therapy,	and	 long-term	R0	resection	expectations.	 In	patients	who	are	18	 not	 candidates	 for	 surgery,	 percutaneous	 image-guided	RFA	 is	 a	 locally	 effective	 treatment	19	 and	chemoembolization	 is	 another	possibility	 to	 treat	 liver	metastases.	RFA	 in	 combination	20	 with	surgical	resection	may	allow	better	disease	control	in	the	setting	of	limited	disease	[58-21	 60].	 Tumor	debulking	 generally	 offers	 little	 benefit,	 however	 surgery	 of	 primary	 disease	 in	22	 newly	 diagnosed	 patients	 with	 oligo-metastatic	 disease	 and	 limited	 exta-adrenal	 tumor	23	 volume	can	be	performed	 in	 case	of	 good	 response	 to	 systemic	 therapy.	 It	 should	be	noted	24	 that	the	efficacy	of	local	regional	therapies	in	the	management	of	such	patients	has	never	been	25	
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assessed	in	a	randomized	prospective	clinical	 trial,	so	we	cannot	exclude	that	the	 long-term	1	 benefit	obtained	in	some	cases	can	be	ascribed	to	a	patient	selection.	 In	the	author	opinion,	2	 the	long-term	benefit	is	due	at	least	in	part	to	the	efficacy	of	systemic	therapy;	therefore,	it	is	3	 recommended	that	all	local	regional	approaches	should	be	used	in	combination	with	systemic	4	 therapy.				5	 On	the	contrary,	the	majority	of	metastatic	ACC	patients	have	poor	prognostic	features	(i.e.	2	6	 or	more	organ	involved).	For	these	patients,	chemotherapy	with	EDP-M	regimen	represents	7	 the	 treatment	 of	 choice.	 In	 case	 of	 painful	 metastasis,	 palliative	 radiotherapy	 is	 an	 option,	8	 especially	in	bone	lesions.		Due	to	the	latency	of	mitotane	to	attain	the	therapeutic	range,	the	9	 drug	administered	alone	is	not	indicated	in	the	management	of	patients	with	clinical	evidence	10	 of	 fast	 growing	 tumors.	 Metastatic	 ACC	 submitted	 to	 EDP-M	 regimen	 have	 a	 survival	11	 perspective	of	18	months	as	demonstrated	by	the	results	of	the	FIRM-ACT	trial	[56].	However,	12	 15%	of	patients	are	alive	after	5	years.	In	terms	of	PFS,	50%	of	patients	submitted	to	EDP-M	13	 showed	disease	progression	after	5	months,	and	25%	of	patients	were	free	from	progression	14	 after	12	months,	and	15%	after	2	years.	In	addition,	few	patients	were	still	alive	and	free	from	15	 progression	 after	 5	 years	 [56].	 These	 data	 show	 that	 the	 efficacy	 of	 chemotherapy	 plus	16	 mitotane	 is	 overall	modest,	 but	 a	 small	 subset	of	patients	 is	destined	 to	obtain	 a	 long-term	17	 disease	control.	The	 identification	of	 factors	 that	may	predict	chemotherapy	efficacy	 is	very	18	 important	to	select	patients	destined	to	benefit	from	this	aggressive	strategy	and	to	address	19	 non-responding	patients	to	experimental	therapies.	In	a	recently	published	paper,	our	group	20	 has	demonstrated	that	the	expression	of	topoisomerase	II	was	associated	with	EDP-M	efficacy	21	 [61].	 These	 data	 need	 confirmation.	 It	 should	 be	 noted,	 however,	 that	 EDP	 is	 usually	22	 administered	 for	 a	 maximum	 of	 6-8	 cycles	 while	 mitotane	 is	 usually	 maintained	 till	23	 progression.	 It	 is	 possible	 that	 cytotoxic	 chemotherapy	 is	 useful	 to	 attain	 rapid	 tumor	24	 shrinkage	 but	 the	 long-term	 efficacy	 observed	 in	 some	 cases	 could	 be	 attributed	 to	 the	25	
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mitotane	 maintenance.	 If	 this	 is	 true,	 predictive	 factors	 of	 mitotane	 efficacy	 are	1	 needed.		Human	cytochrome	P450	2B6	(CYP2B6)	[62]	and	CYP2W1	[63]	that	are	involved	in	2	 mitotane	metabolism	and	may	activate	mitotane	in	the	adrenocortical	tissue,	respectively,	or	3	 ribonucleotide	 reductase	 large	 subunit	 1	 (RRM1)	 gene	 expression	 [64]	 are	 promising	4	 predictive	factors	of	mitotane	efficacy.	The	value	of	these	potential	predictive	factors	should	5	 be	assessed	in	prospective	studies.	6	 Finally,	 regarding	 second-line	 therapy,	 the	 results	 of	 patients	 with	 disease	 progression	 to	7	 platinum-containing	 regimens	 plus	 mitotane	 were	 as	 a	 whole	 modest.	 The	 association	 of	8	 gemcitabine	 to	 metronomic	 capecitabine	 showed	 a	 limited	 activity	 in	 a	 prospective	9	 multicenter	 phase	 II	 trial	 conducted	 in	 Italy	 [65].	 Results	 have	 been	 confirmed	 a	 series	 of	10	 patients	treated	in	a	real	world	practice	both	in	Germany	and	in	Italy	[66].	This	regimen	still	11	 remains	the	most	used	option	as	second	line	therapy.	Several	small	phase	II	trials	have	tested	12	 the	 efficacy	 of	 molecular	 agents	 targeting	 EGFR,	 angiogenesis,	 IGFR,	 and	 mTOR	 pathways.	13	 These	 treatments	 administered	 in	 pre-treated	 patients	 either	 alone	 or	 in	 combination	with	14	 chemotherapy,	 or	 with	 other	 molecular	 target	 agents	 obtained	 poor	 results	 [67-69].	 In	 a	15	 multicenter	 randomized	 phase	 III	 trial	 involving	 most	 referenced	 centers	 in	 Europe	 and	16	 United	 States,	 the	 drug	 Linsitinib	 (OSI-906),	 an	 orally	 available	 IGFR	 inhibitor	 failed	 to	17	 demonstrate	a	superiority	over	placebo	in	terms	of	both	progression	free	and	overall	survival	18	 in	 advanced	 pre	 treated	 ACC	 patients	 [70].	 Also	 modern	 immunotherapy	 failed	 to	 show	19	 efficacy	in	advanced	ACC.	In	a	phase	1b	cohort	(NCT01772004),	50	patients	with	metastatic	20	 ACC	and	prior	platinum-based	therapy	received	avelumab	at	10 mg/kg	IV	every	2	weeks,	until	21	 progression.	 Only	 2	 patients	 (5%)	 attained	 a	 disease	 response	 while	 PFS	 was	 5.5	 and	 1.5	22	 months	in	patients	with	PDL-1	positive	and	negative	ACC	patients,	respectively	[71].			23	 	24	
	25	
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5.	ENDOCRINE	MANAGEMENT	OF	CORTISOL	SECRETING	ACC	1	 The	morbidity	caused	by	ACC	and	its	prognosis	derives	not	only	from	the	spread	of	malignant	2	 cells	into	other	organs	but	also	from	the	consequences	of	hormone	excess.	Consequently,	the	3	 goals	of	treatment	in	ACC	include	both	control	of	tumor	growth	and	mitigation	of	the	effects	4	 derived	 from	 hormone	 excess	 in	 patients	 with	 hormone-secreting	 ACC.	 As	 uncontrolled	5	 hypercortisolism	strongly	impacts	on	quality	of	life	and	may	cause	a	precocious	death,	a	rapid	6	 control	of	hormone	hypersecretion	 is	mandatory.	Mitotane	has	both	anti-secretive	and	anti-7	 proliferative	activity;	however,	the	slow	onset	of	mitotane	activity	is	a	main	limitation	for	the	8	 management	of	 Cushing’s	 syndrome	 [26].	 Faster	drug	 in	 lowering	 serum	cortisol	 levels	 are	9	 needed,	such	as	metyrapone,	ketoconazole,	etomidate	[72].	A	case	series	of	14	patients	with	10	 severe	neoplastic	hypercortisolism,	including	8	ACC,	have	been	treated	with	a	combination	of	11	 metyrapone	and	ketoconazole	in	two	tertiary-care	university	hospitals.	In	patients	with	ACC,	12	 median	UFC	after	1	week	of	 treatment	 fell	 from	16.0	 to	1.0	ULN	(upper	 limit	of	 the	normal	13	 range)	 and	 after	 1	 month	 UFC	 values	 were	 normal	 in	 86%	 of	 patients.	 Also	 important	14	 improvements	of	clinical	status,	kalaemia,	glycaemia	and	blood	pressure	were	reported,	with	15	 decrease	 in	 drugs	 used	 for	 co-morbidities.	 Side	 effects	were	minimal	 and	 only	 one	 patient	16	 with	 ACC	 had	 plasma	 transaminase	 increase,	 necessitating	 ketoconazole	 withdrawal.	 The	17	 study	 concluded	 that	metyrapone–ketoconazole	 combination	 is	well	 tolerated	 and	 allows	 a	18	 rapid	 control	 of	 life-threatening	 ACC	 induced	 hypercortisolism	 [73].	 Recently,	 Claps	 and	19	 colleagues	 [74]	 reported	 three	 cases	 of	 advanced	 ACC	 patients	 with	 Cushing’s	 syndrome	20	 treated	 with	 a	 combination	 of	 metyrapone	 and	 EDP-M.	 The	 case	 series	 showed	 that	 this	21	 treatment	 was	 effective	 and	 well	 tolerated,	 inducing	 a	 rapid	 control	 of	 hypercortisolism	22	 caused	by	cortisol-secreting	ACC.	23	
On	 a	 separate	 note,	 it	 is	 important	 to	 offer	 advice	 about	 the	 potential	 concerns	 of	24	
becoming	pregnant	after	removal	of	an	ACC.	There	is	limited	evidence	suggesting	that	25	
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pregnancy	 may	 trigger	 ACC	 recurrence	 and	 that	 pregnancy	 in	 patients	 with	 past	 or	1	
current	 ACC	may	 be	 associated	with	 worse	 prognosis	 [75,	 76].	 Moreover,	 pregnancy	2	
should	 be	 avoided	while	 being	 exposed	 to	mitotane,	 due	 to	 its	 potential	 teratogenic	3	
effects.	 In	 this	 context,	 it	 is	 important	 to	 recognize	 that	mitotane	 levels	may	 remain	4	
measurable	for	many	months	following	discontinuation	of	treatment.	5	
	6	
Expert	commentary:		7	 Management	 of	 ACC	 patients	 is	 fraught	 with	 many	 difficulties	 and	 should	 be	 limited	 to	8	 experienced	physicians.	Each	step	of	clinical	management,	such	as	diagnosis,	prognostication,	9	 treatment	 (both	 surgical	 and	 medical)	 is	 challenging	 and	 carries	 the	 possibility	 of	 severe	10	 mistakes.	 For	 this	 reasons,	 each	 step	 of	 the	management	 strategy	 should	be	decided	 in	 the	11	 setting	 of	 a	multi-disciplinary	 team	 including	 different	 expertise	 (endocrinology,	 radiology,	12	 pathology,	oncology).	First,	pre-surgical	diagnosis	should	be	accomplished	with	a	number	of	13	 different	tests	(both	radiological	and	hormonal)	in	the	least	time	possible.	Second,	it	is	of	the	14	 utmost	importance	that	surgery	be	done	in	high-volume	centers	to	offer	the	best	possibility	of	15	 radical	resection	to	the	patients.	This	remains	the	single	most	 important	 therapeutic	act	 for	16	 ACC	patients.	Third,	careful	selection	of	patients	for	adjuvant	or	palliative	therapies	should	be	17	 undertaken,	and	treatments	should	be	given	in	expert	centers.	In	these	centers,	patients	may	18	 be	 offered	 the	 chance	 to	 participate	 in	 clinical	 trials	 with	 experimental	 drugs	 due	 to	 the	19	 limited	availability	of	current	therapeutic	choices.	20	
	21	
Five-year	view:		22	 Recent	 studies	 [77],	 [78]	 provided	 great	 advances	 in	 the	 understanding	 of	 molecular	23	 pathogenesis	of	ACC	and	led	to	the	definition	of	groups	characterized	by	different	molecular	24	 signature	and	different	prognosis.	It	is	expected	that	over	the	next	few	years	the	use	of	these	25	
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molecular	markers	will	be	applicable	in	clinical	practice	thus	representing	the	cornerstone	for	1	 prognostication	 and	 stratifying	 treatment	 strategy.	 This	 will	 be	 the	 first	 step	 toward	 a	2	 personalized	therapy;	as	instance,	patients	in	the	“good	prognosis	group”	may	be	potentially	3	 spared	 adjuvant	 mitotane	 treatment	 while	 patients	 in	 the	 “poor	 prognosis	 group”	 may	 be	4	 treated	more	 intensively.	 	As	 to	adjuvant	mitotane	 treatment,	 the	conclusion	of	 the	ongoing	5	 ADIUVO	and	ADIUVO-2	study,	which	is	about	to	be	launched,	will	provide	important	data	for	6	 defining	 the	 value	 of	 adjuvant	mitotane	 in	 either	 “low-risk”	 or	 “high-risk”	 patients.	 Finally,	7	 molecular	studies	will	hopefully	detect	targets	that	can	be	druggable,	thus	paving	the	way	for	8	 future	 targeted	 therapies	 with	 more	 efficacy	 and	 less	 toxicity	 compared	 to	 the	 current	9	 therapeutic	options.	This	remains	the	most	urgent	need	in	the	management	of	advanced	ACC.	10	 	11	
KEY	ISSUES	12	
• Adrenocortical	carcinoma	(ACC)	is	a	rare	tumor	that	should	be	diagnosed	and	treated	13	 promptly	due	to	its	very	aggressive	behavior.		14	
• 			ACC	 is	 frequently	 associated	with	 Cushing’s	 syndrome	 that	may	 have	 severe	 clinical	15	 consequences,	 including	 a	 strong	 impact	 on	 quality	 of	 life	 and	 reduction	 of	 life	16	 expectancy.	17	
• Surgery	is	the	treatment	of	choice	and	should	be	attempted	whenever	radical	resection	18	 is	feasible.		19	
• Despite	radical	surgery,	ACC	has	a	high	propensity	to	recur,	particularly	when	adverse	20	 prognostic	factors	are	present.	21	
• Mitotane	 is	the	only	approved	drug	for	ACC	and	is	used	either	as	adjuvant	treatment	22	 following	surgical	removal	of	the	tumor	or	palliative	treatment	for	advanced	disease.		23	
• Mitotane	 is	 a	 difficult	 drug	 to	manage	 and	 either	monitoring	 of	 circulating	 levels	 or	24	 institution	of	appropriate	supportive	therapy	is	a	key	to	limit	drug-related	toxicity.				25	
	 22	
• Standard	 treatment	 of	 advanced	 ACC	 includes	 the	 chemotherapy	 regimen	 EDP	1	 (etoposide,	doxorubicin,	cisplatin)	in	association	with	mitotane.	2	
• Medical	 treatment	 of	 ACC	 is	 still	 underdeveloped	 and	 has	 limited	 efficacy.	3	 Hypercortisolism	should	be	promptly	corrected	by	using	mitotane	in	combination	with	4	 a	faster	inhibitor	of	steroidogenesis,	such	as	metyrapone.		5	 	6	 	7	
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